PubMed Health⌕ Search

Biomedical subjects

L Dominguez-Gadea

Publications and source records attributed to L Dominguez-Gadea.

5 recordsLinked to original sources
PubMed1996

Scintigraphic diagnosis of subclinical Cushing's syndrome in patients with adrenal incidentalomas.

Adrenal scintigraphy has been shown to be a useful procedure for the characterization of incidentally discovered adrenal tumours. The functional evaluation of these patients is controversial. This paper describes the biochemical and pathological findings in five patients with asymptomatic adrenal masses and unilateral concordant adrenocortical scintigraphic uptake. All the patients were diagnosed as having subclinical Cushing's Syndrome, without clinical or biochemical adrenocortical dysfunction. Scintigraphy is the most sensitive method for detecting an adrenal adenoma in the subclinical setting when the disease is not yet demonstrable by biochemical methods.

Adrenal Cortex↗
PubMed1994

Differential diagnosis of solid adrenal masses using adrenocortical scintigraphy.

To evaluate the diagnostic contribution of adrenal scintigraphy with 75-Se-selenomethylcholesterol in adrenal masses, 42 patients have been studied. All of them had a solid adrenal mass discovered on computed tomography (seven bilateral). None of the patients showed any symptoms or clinical signs that might indicate the existence of adrenal dysfunction. Twenty-nine of them had known extra-adrenal primary malignant disease. Forty-nine adrenal tumours were detected with an average size of 3.29 cm (range 1.5-12 cm). Eighteen lesions showed increased uptake of radiocholesterol on the side of the adrenal mass, all of which were either proven to be benign, or behaved in a benign fashion. Twelve lesions showed normal uptake (10 in the benign group and one lung carcinoma metastasis), all but one (2.5 cm) being smaller than 2 cm. Decreased uptake was observed in 20 lesions (15 metastases, two nonfunctional adrenal carcinomas, one myelolipoma and two tuberculous infectious lesions). Adrenocortical scintigraphy provides functional information about adrenal masses and is useful in differentiating between benign and malignant lesions.

Adrenal Gland Neoplasms↗
PubMed1993

Diabetic foot infections: scintigraphic evaluation with 99Tcm-labelled anti-granulocyte antibodies.

Thirty-eight lesions found by physical and/or radiological examination in 25 patients with long-term diabetes mellitus were studied in order to evaluate the clinical utility of immunoscintigraphy using 99Tcm-labelled anti-granulocyte monoclonal antibodies (MAb BW 250/183) for the diagnosis of infectious pathology in diabetic foot. All the patients underwent three-phase bone scintigraphy with 740 MBq 99Tcm-methylene disphosphonate. Immunoscintigraphy was performed 4 and 24 h after administration of 500 MBq of the labelled antibody by planar selective views. Uptake intensity was scored 0 to 4 (0 = normal, 1 = mildly increased, 2 = moderately increased, 3 = intense, 4 = very intense) when compared with adjacent or contralateral uninvolved bone marrow and soft tissue. Several projections were performed and anatomical references of bone scan were used to determine whether the lesion involved the bone or soft tissue. Definitive diagnoses were 15 osteomyelitis, 14 soft tissue lesions (nine cellulitis and five noninfected ischaemic or trophic wounds), and nine degenerative bone disease. 99Tcm-granulocyte scintigraphy showed increased uptake in seven soft tissue lesions, in four of which exclusively soft tissue involvement was demonstrated by scintigraphy. Only one false negative scintigraphic finding was observed (chronic osteomyelitis). No abnormal anti-granulocyte antibody uptake was observed in degenerative lesions. Based on our observations, immunoscintigraphy with 99Tcm-MAb BW250/183 has a sensitivity of 93% in the diagnosis of osteomyelitis involving diabetic patients' feet. Although it is feasible to distinguish exclusive soft tissue involvement, this is still the main cause of misdiagnosis in current clinical practice.

Adult↗
PubMedDate not supplied

MCA serum determination in breast carcinoma patients for the diagnosis of bone metastases.

Serum MCA levels were determined in 173 consecutive patients with breast cancer in order to assess the clinical utility of MCA for the detection of bone metastases. Bone pathology was diagnosed by scintigraphy, radiology and clinical follow-up. Metastases were found in 37 patients, benign lesions in 25, and in 111 no bone lesions were found. Eighteen of the 173 bone scans were considered indeterminate for metastases. Based on the receiver-operating characteristic curves (ROC) analysis, the cut-off level for MCA was set at 20 U/ml. Only in 4 of the 37 patients with bone metastases MCA was below 20 U/ml. All 4 patients had completed their chemotherapy course within six months before MCA determination. Only in 6 patients of the 136 without bone metastases MCA levels were above 20 U/ml. Of the 18 patients with indeterminate bone scans, 15 had benign lesions and all of them had MCA levels below 20 U/ml. MCA determination is a sensitive method for the detection of bone metastases in breast carcinoma. We encourage the use of this procedure for the selection of high-risk groups or as a complementary method for the interpretation of bone scintigraphy.

Adult↗